Top Core and Group Health Stories
Oncology drugs lead the way for new approvals in 2020
By Scott WooldridgeA new report from OptumRx also expects to see 11 drugs representing potential blockbuster sales of more than $1 billion each.
News, insight, and analysis from industry experts to help benefits brokers, consultants and advisors make their way through the tumultuous reformed health care marketplace. Content will help them grow their practices by focusing on a wide range of products, discussing new sales and marketing strategies and highlighting innovative and disruptive brokers who are forging a new path in today's benefits marketplace.
A new report from OptumRx also expects to see 11 drugs representing potential blockbuster sales of more than $1 billion each.